Gain Therapeutics' GT-02287 Shows Durable Parkinson's Disease Stabilization in Phase 1b Extension — Gain Therapeutics, Inc.

Event summary

GT-02287 demonstrated stable MDS-UPDRS scores after 150 days in Phase 1b extension study
4.8-point difference in MDS-UPDRS scores between high and low baseline GluSph groups
16 of 19 participants continued into nine-month extension, supporting tolerability
Phase 2 trial to include new endpoints for smell, gait, and sleep assessments

The big picture

Gain Therapeutics' positive Phase 1b extension data for GT-02287 positions the company as a potential leader in disease-modifying Parkinson's treatments. The results suggest the drug may address both idiopathic and GBA1-associated forms of the disease, expanding its potential market. The focus on non-motor symptoms like smell and gait aligns with growing industry emphasis on comprehensive Parkinson's disease management.

What we're watching

Biomarker Correlation: Whether the 4.8-point MDS-UPDRS difference between GluSph groups will persist through Phase 2
Regulatory Pathway: The pace at which Gain can translate these results into a Phase 2 design acceptable to regulators
Competitive Positioning: How Gain's allosteric modulator approach differentiates against emerging Parkinson's disease therapies